Insider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases 4,137 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 4,137 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was bought at an average cost of $9.14 per share, for a total transaction of $37,812.18. Following the purchase, the insider now owns 5,090,582 shares in the company, valued at $46,527,919.48. This represents a 0.08 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 7th, Venrock Healthcare Capital Par purchased 73,649 shares of KalVista Pharmaceuticals stock. The stock was bought at an average cost of $9.29 per share, with a total value of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The shares were bought at an average cost of $9.22 per share, for a total transaction of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average cost of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Trading Up 0.9 %

Shares of KALV traded up $0.08 during mid-day trading on Tuesday, reaching $9.27. The company had a trading volume of 239,790 shares, compared to its average volume of 293,951. The stock has a market cap of $458.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.85. The firm has a fifty day simple moving average of $8.75 and a 200-day simple moving average of $10.58. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.01. As a group, equities analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. State Street Corp grew its stake in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after acquiring an additional 515,179 shares in the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in KalVista Pharmaceuticals in the fourth quarter valued at about $634,000. Vestal Point Capital LP grew its stake in KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after purchasing an additional 1,700,000 shares in the last quarter. Barclays PLC grew its stake in KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 54,257 shares in the last quarter. Finally, Readystate Asset Management LP purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $2,084,000.

Wall Street Analysts Forecast Growth

KALV has been the subject of a number of recent research reports. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Finally, JMP Securities assumed coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an “outperform” rating and a $19.00 target price for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).